Search company, investor...

Inflazyme Pharmaceuticals

inflazyme.com

Stage

Other Investors | Alive

About Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Headquarters Location

5600 Parkwood Way Ste 425

Richmond, British Columbia, V6V 2M2,

Canada

Missing: Inflazyme Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Inflazyme Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Inflazyme Pharmaceuticals News

Inflazyme, Hoechst Marion Roussel to Develop Asthma/Allergy Drugs

Jan 6, 2018

Inflazyme Pharmaceuticals Ltd. (Richmond, BC, Canada) and Hoechst Marion Roussel (Kansas City, MO) have signed a collaborative agreement to develop two novel series of compounds—Inflazyme's IPL576 series and Hoechst Marion Roussel's H1/NK1 dual antagonists—for the treatment of asthma and allergies. Under terms of the agreement, Inflazyme will receive an up-front fee and an equity investment by Hoechst Marion Roussel totaling up to US$16 million. In addition, Inflazyme will be entitled to payments totaling US$75 million if development milestones specified in the agreement are achieved. The agreement gives Inflazyme immediate access to cash for the development of IPL576 and H1/NK1, while minimizing dilution to the company's common shareholders. Inflazyme expects to enter Phase I clinical trials with IPL576,092 in the UK before the end of June. IPL576,092 is Inflazyme's lead clinical candidate from its IPL576 class of compounds, which is based on a molecule originally isolated from a sea sponge by researchers at the University of British Columbia and the University of Alberta. Pre-clinical studies have demonstrated that IPL576,092 may have the efficacy of inhaled glucocorticoids without the related side effects. Hoechst Marion Roussel's H1/NK1 dual antagonists combine in a single molecule an antihistamine and a neuro-peptide inhibitor. In pre-clinical studies to date, H1/NK1 dual antagonist compounds have demonstrated antagonist activity at both the H1 and NK1 receptors, which indicates that they may have the potential to relieve both the itchiness and the congestion associated with allergies. In addition to the development agreement, Inflazyme and Hoechst Marion Roussel have agreed to collaborate on research into the mode of action and cellular targets for IPL576. The two companies will share ownership of joint discoveries from the research collaboration. Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat serious inflammatory diseases such as asthma, rheumatoid arthritis, allergies, psoriasis and inflammatory bowel disease. Hoechst Marion Roussel is the pharmaceutical company of Hoechst AG (Frankfurt, Germany). For more information: Ian McBeath, President and CEO, Inflazyme Pharmaceuticals Ltd., Suite 425, 5600 Parkwood Way, Richmond, British Columbia V6V 2M2, Canada. Tel: 604-279-8511. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .

Inflazyme Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Inflazyme Pharmaceuticals's headquarters?

    Inflazyme Pharmaceuticals's headquarters is located at 5600 Parkwood Way, Richmond.

  • What is Inflazyme Pharmaceuticals's latest funding round?

    Inflazyme Pharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Inflazyme Pharmaceuticals?

    Investors of Inflazyme Pharmaceuticals include Domain Associates.

  • Who are Inflazyme Pharmaceuticals's competitors?

    Competitors of Inflazyme Pharmaceuticals include Array Biopharma, BioMarck Pharmaceuticals, Idenix Pharmaceuticals, Quincy Bioscience, Syntaxin, Esperion Therapeutics, Aerovance, Alba Therapeutics, RespiVert, Cequent Pharmaceuticals and 19 more.

Compare Inflazyme Pharmaceuticals to Competitors

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

D
Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

N
Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

T
Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.

T
Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.

A
Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.